Codexis (CDXS) Competitors

Myriad Genetics (NASDAQ:MYGN) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends.

Do analysts recommend MYGN or CDXS?

Myriad Genetics currently has a consensus price target of $21.89, indicating a potential upside of 124.08%. Codexis has a consensus price target of $8.33, indicating a potential upside of 184.90%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.20
Codexis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Is MYGN or CDXS more profitable?

Myriad Genetics has a net margin of -14.09% compared to Codexis' net margin of -96.35%. Myriad Genetics' return on equity of -4.51% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-14.09%	-4.51%	-3.07%
Codexis	-96.35%	-71.56%	-38.00%

Do insiders & institutionals have more ownership in MYGN or CDXS?

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by insiders. Comparatively, 2.1% of Codexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has higher earnings & valuation, MYGN or CDXS?

Codexis has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$837.60M	1.07	-$263.30M	-$1.41	-6.93
Codexis	$59.35M	4.08	-$76.24M	-$0.90	-3.25

Does the media prefer MYGN or CDXS?

In the previous week, Myriad Genetics had 1 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Myriad Genetics and 4 mentions for Codexis. Myriad Genetics' average media sentiment score of 1.00 beat Codexis' score of 0.59 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, MYGN or CDXS?

Myriad Genetics has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.

Does the MarketBeat Community prefer MYGN or CDXS?

Myriad Genetics received 123 more outperform votes than Codexis when rated by MarketBeat users. However, 61.47% of users gave Codexis an outperform vote while only 52.78% of users gave Myriad Genetics an outperform vote.

Company	Underperform	Outperform
Myriad Genetics	Outperform Votes 474 52.78%	Underperform Votes 424 47.22%
Codexis	Outperform Votes 351 61.47%	Underperform Votes 220 38.53%

Summary

Myriad Genetics beats Codexis on 9 of the 17 factors compared between the two stocks.